Skip to content

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Pfizer logo
PfizerPFE
$2.18B+23.0%
Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
Amgen logo
AmgenAMGN
$1.48B+50.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%

Valuation

See full
Market cap$40.63B+495%
Enterprise value$40.35B+515%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Calculated from Revolution Medicines, Inc.’s reported figures.

The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revolution Medicines, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revolution Medicines, Inc.'s free cash flow?
Revolution Medicines, Inc. (RVMD) reported free cash flow of -$355.7M in Q1 2026.
How has Revolution Medicines, Inc.'s free cash flow changed year-over-year?
Revolution Medicines, Inc.'s free cash flow decreased by 79.9% year-over-year, from -$197.7M to -$355.7M.
What is the long-term trend for Revolution Medicines, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s free cash flow has grown at a 56.1% compound annual growth rate (CAGR), from -$153.71M to -$913.73M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.